1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  Access will be restricted to the investigator and the supervisor, and the REB members on demand. The findings of the study based on the collective data will be published without identifying the individual.


6. For how long will this data be available start date provided 12-12-2027 and end date provided 12-12-2036?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

The study will be conducted on, “The effect of nebulised Dexmedetomidine on hemodynamic response to laryngoscopy and intubation in patients undergoing surgery under general anaesthesia. A Randomised Clinical Trial. Here in our study, patients will be randomly allocated into two groups using a computer-generated block randomization sequence. A total of 52 ASA grade 1 or 2 patients, aged 18–60 years, of either gender, will be randomly allocated into two groups. Patients allocated into Group D will receive nebulized dexmedetomidine (0.5mcg per kg) and Group N will receive nebulized normal saline. The study drug will be prepared by an anaesthesiologist not directly involved in the study, as a uniform 5 ml solution. Allocation concealment will be ensured using sequentially numbered opaque sealed envelopes. The study drug will be administered as aerosol using an electric compressor nebulizer in a propped up or semi recumbent position 30 minutes before induction of general anaesthesia. Nebulization will be done with a 200 cm tubing connected from the oxygen port (100 percent oxygen at a flow rate of 10L per min) attached with a nebulisation mask. Nebulization will continue until the entire solution in the nebulizer gets aerosolized (10 to 15 mins). The anaesthetist blinded to the study will record the following parameters, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and SpO2, at the following time points, at baseline (before nebulization), after nebulization but before induction, during laryngoscopy and intubation, at 1 minute, 3 minutes, 5 minutes, 7 minutes and 10 minutes post-intubation. The observations made during the study will be tabulated, graphically depicted whenever possible, statistically analysed and inferences will be drawn to study the effect of airway nebulization with dexmedetomidine (0.5 mcg per kg) on stress response to laryngoscopy and intubation.